YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
On September 25, Johnson & Johnson (NYSE:JNJ) announced top-line findings from its Phase 4 STAR study evaluating Tremfya (guselkumab) in biologic-naïve adults with active psoriatic arthritis (PsA) and axial involvement. Tremfya met primary…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ipsen stock has more than doubled over the past five years, yet the latest valuation checks send mixed signals. The Discount…
It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core ear…
Guardant Health, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap her…
MISSISSAUGA, ON, July 15, 2026 /PRNewswire/ -- Septa Pharmaceuticals Inc., a rapidly growing leader in the Canadian healthcare sector, is proud to announce the successful acquisition of CeeNU® (Lomustine) from Bristol Myers Squibb, Canada…
AUSTIN, Texas, May 07, 2026--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026. Recent Financial Highlights G…
Johnson & Johnson Q1 2026 Earnings Call Summary - Moby Strategic Performance Drivers Achieved 6.4% operational sales growth, fueled by a record-strength portfolio and pipeline across six key focus areas including Oncology, Immunology, and…
AstraZeneca’s growth engine stays on track despite cost pressures Proactive uses images sourced from Shutterstock AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) full-year results showed the pharmaceutical group navigating a challenging comparison…
Focused Execution Drives Strong Full-Year 2025 EPS Performance Enters 2026 with Clear Strategic Priorities and Growing Late-Stage Pipeline Advanced 11 Key Pivotal Study Starts in 2025 and ~20 Key Pivotal Study Starts Planned for 2026 NEW Y…
IRVING, Texas, January 30, 2026--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it has closed the transaction to sell its retail and distribution businesses in Norway to NorgesGruppen, a privately owned retail group…
Medical services stock Guardant Health is Thursday's selection for IBD 50 Stocks To Watch after catapulting 234% in 2025, thanks to steady sales growth for its noninvasive cancer screening and diagnostic services. Guardant Health stock rec…
Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On October 19, Pfizer Inc. (NYSE:PFE) and Astellas Pharma US Inc. announced final overall survival results from their Phase 3 EMBARK study. The stud…
Tempus AI, Inc. TEM reported a second-quarter 2025 adjusted loss of 22 cents per share, narrower than the Zacks Consensus Estimate by 4.35%. GAAP loss per share was 25 cents compared with a loss of $6.86 year over year. TEM’s Q2 Revenues R…
AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earn…
SAN FRANCISCO, CA, March 31, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has provided the initial financing for the initiation of formal drug development and preclinical plan…
SAN FRANCISCO, CA, March 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) revealed today the Company’s plans for growth and development of its intellectual property and business model. Key focal points incl…
SAN FRANCISCO, CA, March 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) revealed today the Company’s plans for growth and development of its intellectual property and business model. Key focal points incl…
San Francisco, CA, March 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Oncology Pharma Inc. (OTC: ONPH): Today, the company announced it is putting together a short list of contract research organizations (CROs) to assist in developing…
San Francisco, CA, March 04, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Oncology Pharma Inc. (OTC: ONPH) is pleased to announce initiation of formal drug development and preclinical planning for its lead drug product, based upon propriet…
San Francisco, CA, Feb. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Oncology Pharma Inc. (OTC: ONPH) is pleased to announce that it has executed a world-wide Licensing Agreement with Sybleu Inc. for its Cancer therapy by intratumoral…
SAN FRANCISCO, CA, Feb. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has extended a world-wide Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in the gro…
SAN FRANCISCO, CA, Feb. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that Dr. Henry Smith has accepted the role of Chairman of the Scientific Advisory Board. Dr. Henry Smith has o…
San Francisco, CA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Oncology Pharma Inc. (OTC: ONPH) is pleased to announce that it has renewed its world-wide Licensing Agreement with Ribera Solutions (under its tradename “Connect2Med…
SAN FRANCISCO, CA, Feb. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has extended its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in Human Oncology. N…
San Francisco, CA, Jan. 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Oncology Pharma Inc. (OTC: ONPH) is pleased to announce that it has retained the services of Mr. James Smith, CPA as its new Chief Financial Officer. Mr. James Smith,…
San Francisco, CA, Aug. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma, Inc. (OTCPK: ONPH) is pleased to announce that it has extended its Letter of Intent with Kalos Therapeutics. George Malasek was brought into the Comp…
SAN FRANCISCO, CA, April 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ‒ Oncology Pharma, Inc. (OTCPK: ONPH) and Kalos Therapeutics (“Kalos”) announced today that the companies amended the terms of their collaboration to explore treatment…
San Francisco, CA, March 11, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma, Inc. (OTCPK: ONPH) is pleased to announce that it is continuing its relationship with NanoSmart Pharmaceuticals, Inc. and has extended its Licensing…
San Francisco, CA, Jan. 28, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma, Inc. (OTCPK: ONPH) would like to inform investors that it has completed its relationship with Tulynode Biosciences, Inc., and will be focusing on ant…
SAN FRANCISCO, CA, Dec. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – ONCOLOGY PHARMA, INC. (OTCPK: ONPH) is pleased to announce that it has received a letter of intent dated December 20th to facilitate a financing of US$ 38.4 Million fr…
SAN FRANCISCO, CA, Dec. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – ONCOLOGY PHARMA, INC. (OTCPK: ONPH) is pleased to announce that it has received a letter of intent dated December 20th to facilitate a financing of US$ 38.4 Million fr…
San Francisco, CA, Dec. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma, Inc. (OTC: ONPH) announced today that it has signed a Letter of Intent (LOI) to acquire at least a 50% stake in Diagnomics, Inc., a private CLIA cert…
San Francisco, CA, Nov. 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma Inc. (OTCPK: ONPH) is pleased to announce that it has entered into an agreement with Ribera for its clinical trial platform, “Connect2Med”. The licens…
San Francisco, CA, Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma, Inc. is pleased to announce today that Vijay Mahant (M.S, Ph.D.) has been appointed as the Chief Scientific Officer (CSO) of Oncology Pharma and its…
San Francisco, CA, Oct. 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma Inc. is pleased and honored to announce that Stefan Gruenwald (MD, PhD), cofounder and president of Diagnomics Inc., has been elected to Oncology Phar…
SAN FRANCISCO, CA, Sept. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma (OTCPK: ONPH) is pleased to announce that Kalos Therapeutics' lead compound, KTH-222, can produce a reduction in the attachment of newly seeded cells…